Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

Bayer has overturned a ruling that it brought discredit on the pharma industry. | Bayer has overturned a ruling that it brought discredit on the pharma industry. Accused of “warming the market” for a ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Bayer’s strong first quarter performance was mainly driven by its pharmaceuticals division, even as its crop-science branch ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster ...

Bayer said an adverse verdict in a US glyphosate lawsuit, which it is appealing against, had added to litigation costs. The company has also filed a petition with the US Supreme Court and has ...